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Introduction
NGS Establishment in Multidisciplinary Healthcare (NEMHESYS) is an Erasmus+ pro-
gramme with the purpose of providing qualified staff with the essential technical and bio-
informatic knowledge and skills on next-generation sequencing (NGS) to be able to carry 
out NGS studies and perform some of the most common types of analyses. The clinical 
application of NGS has become easier with advancements in technologies.1 However, the 
investment needed to bring NGS into medical practice remains significant, with the scale 
of knowledge required being unprecedented at most hospitals. In addition, these novel 
technologies bring new challenges in translating NGS to clinical practice, at both techni-
cal and regulatory level, in terms of data management, interpretation of the results, and 
genetic counseling.2,3 All these aspects justify the consideration of what will be the precise 
role of NGS in diagnosis, risk assessment, response prediction, and treatment monitoring, 
today and tomorrow. Thus, to evaluate the implementation of NGS in European health-
care/research centers, a mapping survey was carried out, based on previous NGS mapping 
studies.4,5
Demographics
The purpose of this survey was to summarize and compare the performance of clin-
ical NGS services in Europe regarding the laboratory’s sequencing, interpretation, and 
reporting processes, alongside researchers’ interests and limitations. Through this sur-
vey, we have gained a better understanding of the use of NGS in Europe as a tool to 
improve personalized medicine. The 38-question survey, designed in coordination with all 
partners (University of Salamanca, University of Helsinki, Charité University Medicine 
Berlin, Queen’s University Belfast, Masaryk University, Artificial Intelligence Techniques, 
Mnemotix, and IDImás Gestión), was sent by email to various organizations (public hos-
pitals, research centers, private laboratories, and universities) from 9 different countries 
within Europe between May and July 2020. Questions were formatted as multiple-choice, 
allowing responders to select one or more options, depending on the item. Finally, 
questions were grouped topically, generating the following sections: “Demographic 
Questions,” “State of the Art Use of NGS in your Country,” “Laboratory Characteristics,” 
“Standardization and Interpretation,” “Data Storage,” “Software Tools,” “Reporting,” 
and “Open Question.” The report collates the survey results from 58 European university 
hospitals and other public institutions.
State of the art
The results demonstrated that 78% of respondents use NGS for both research and clinical 
purposes and that almost 100% of the surveyed researchers consider that NGS can contribute 
to patient diagnosis, prognosis, and treatment. Interestingly, only 50% of respondents claimed 
to have a regional/national plan for personalized medicine, highlighting inequalities to patients 
in the provision of state of the art NGS technologies across Europe. Reimbursement for NGS 
testing across Europe was received in 66% of cases from government sources, with ~9% not 
receiving any financial reimbursement.
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Laboratory characteristics
Seventy-four percent of surveyed laboratories perform their 
own NGS tests, while the majority of those outsourcing sent 
tests to regional/national reference centers. More than half of all 
respondents reported that they had performed NGS testing on 
>200 patients in the last year. Targeted panel sequencing was the 
main interest in 93% of surveyed laboratories, in comparison 
to 17%, 32%, and 21% of the laboratories performing whole 
genome sequencing (WGS), whole exome sequencing (WES), or 
transcriptome profiling, respectively. Ninety percent of centers 
processed <50 samples in the last year using WGS, WES, or tran-
scriptome profiling, while half of them processed >200 samples 
by targeted panel sequencing. Thus, centers process consider-
ably fewer samples for WGS, WES, and transcriptome profiling 
than for targeted panel sequencing
Of those surveyed, 85% have access to at least 1 sequencing plat-
form. The most commonly used sequencing platform is Illumina 
(92%), with 22% of respondents using Thermo Fisher Scientific.
Standardization and interpretation
Laboratory standardization was surveyed with regards 
to sample processing/storage, extraction/quantification, and 
sequencing, alongside computational analysis and interpreta-
tion/reporting. The results showed that 81%–91% of wet-lab 
processes were performed in a standardized manner, while only 
66%–78% of computational analyses and interpretation is 
standardized, indicating that there is a disparity between stan-
dardization of wet and dry-lab processes.
The necessity of practice guidance for clinical laboratories 
seeking to develop NGS assays was surveyed, and it was found 
that 98% of researchers deemed it an essential requirement; 
however, there was no consensus on who or which institute 
should develop these guidelines. General international guide-
lines, such as the American College of Medical Genetics Best 
Practice Guidelines for Variant Classification,6 are used by 71% 
of laboratories for the reporting of sequence variants, while 36% 
and 47% refer to general national guidelines or disease-specific 
guidance, respectively.
The profile of those involved with the primary analysis of 
NGS variants is varied; however, almost 60% of the initial 
analysis is performed by doctoral-level clinical scientist fellows/
molecular genetic pathology resident in training, graduate-level, 
or PhD-level trained analyst. In 67% of the surveyed groups, 
filtered variants are never, rarely, or occasionally reviewed by 
a board-certified MD clinical geneticist. Reported variants are 
not confirmed by another methodology in 22% of laboratories. 
Interestingly, 26% of surveyed laboratories do not hold regular 
meetings to discuss challenging cases or filtered variants from 
NGS analysis. Of those who hold regular meetings, it was found 
that the group members were diverse and contributed to a mul-
tidisciplinary approach.
Data storage and software tools
The survey asked what format NGS data are stored, and 
65.5% of laboratories use FASTQ as their main storage modal-
ity, although VCF and BAM files are used to a similar extent 
(50% and 54%, respectively). These files were stored in local/
in-house/LIMS databases in 71% of laboratories, while 20% of 
those surveyed stored their data in commercial software clouds 
such as Alamut Visual or BaseSpace Sequence Hub. Nine per-
cent of laboratories use third-party storage such as Amazon and 
Google. With regards to data processing, 67% of organizations 
questioned have their own pipeline to process NGS data. Most 
preprocessing and analysis of NGS data is performed using R 
(27%), with 35% of respondents not knowing or left the ques-
tion unanswered. Laboratories were asked which tasks were 
accomplished using programming, with 38% of respondents 
using programming to read, preprocess, and visualize the data. 
Conversely, 27% do not use any programming to accomplish 
NGS processing tasks, with 25% not knowing, unsure, or did 
not answer.
Reporting
Laboratories were asked questions referring to the variant 
reporting process. In 76% of the surveyed organizations, the initial 
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draft of the NGS report is written by a doctoral-level clinical 
scientist fellow/molecular genetic pathology resident in training 
graduate level or a PhD-level trained analyst. It was noted that if 
a second review was performed, there was no consensus of who 
typically reviews and edits the test report before the sign-out. 
The professional profile of the NGS report reviewer is varied. 
Interestingly, 9% of respondents claim they either do not have a 
second reviewer or that the question is not applicable to them.
Open question
Researchers were asked what the main bottleneck was in their 
sequencing process, and it was found that there were a variety of 
issues responsible for slowing down the process. Although most 
institutions have standardized the main NGS processes (such 
as sample preparation, library generation, sequencing, compu-
tational analysis, or interpretation), most respondents (31%) 
claimed that a lack of knowledge, training, and exposure to 
routine analyses and interpretation of NGS resulted in the most 
critical bottleneck.
Conclusions and future directions
This survey highlights the disparity across Europe with 
regards to how NGS processes are performed, specifically, the 
lack of standardization when it comes to bioinformatic analysis. 
It has emphasized the need to align NGS processing and bio-
informatic analysis to an internationally recognized guideline, 
alongside providing state of the art training to qualify biomedi-
cal staff to successfully perform clinical NGS at their own insti-
tutions. The patient is the main beneficiary of the application 
of NGS in health care, and it is imperative that they obtain fast 
and precise diagnoses and care. To provide this, specialized bio-
medical personnel equipped with the knowledge and skills are 
required to give the patient assurance that testing is performed 
to the highest standard across Europe. It is, however, clear that 
ensuring the best possible approach to personalized medicine 
and is a complex but essentially unmet need.
Consequently, the NEMHESYS consortium has generated a 
masterclass designed to train the most suitable staff based on 
partners’ experience; this could be clinical scientists, biomedical 
scientists as well clinicians and trainees. The masterclass will 
consist of several modules developed by the Higher Education 
Institution based on their specialization. These modules will be 
made up of masterclasses, case studies, and workshops, favoring 
a dynamic and interactive work environment. It will be taught 
simultaneously via an online platform, with training materials 
available on the website.
Within the NEMHESYS education program, private compa-
nies will run workshops on big data, technological developments, 
artificial intelligence, entrepreneurship, and innovation, provid-
ing participants with practical tasks to strengthen their skills 
and competencies to solve complex problems in their daily 
work. Additionally, the simultaneous connection of participants 
from the different institutions will permit exchange and discus-
sion on these topics. Once educational modules are completed, 
mobility of the NEMHESYS cohorts among participating insti-
tutions will be promoted to complete their training with practi-
cal experience.
More information and updates can be found at https://nem-
hesys.com/
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